S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(-0.19%) $82.65
Gas
(0.60%) $1.663
Gold
(-0.31%) $2 331.10
Silver
(-0.24%) $27.28
Platinum
(-0.25%) $913.50
USD/EUR
(0.01%) $0.935
USD/NOK
(0.04%) $10.99
USD/GBP
(0.05%) $0.803
USD/RUB
(0.02%) $92.34

Realtime updates for Autolus Therapeutics PLC [AUTL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
71.43%
return 14.35%
SELL
28.57%
return 1.74%
Last Updated24 Apr 2024 @ 16:00

-6.03% $ 4.21

SELL 101066 min ago

@ $7.30

Issued: 14 Feb 2024 @ 15:45


Return: -42.29%


Previous signal: Feb 14 - 12:33


Previous signal: Buy


Return: 4.66 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):
Profile picture for Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma...

Stats
Today's Volume 2.72M
Average Volume 1.53M
Market Cap 760.11M
EPS $0 ( 2024-03-14 )
Next earnings date ( $-0.100 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.51
ATR14 $0.0140 (0.33%)

Volume Correlation

Long: -0.34 (neutral)
Short: 0.40 (neutral)
Signal:(41.836) Neutral

Autolus Therapeutics PLC Correlation

10 Most Positive Correlations
PBTS0.943
OP0.94
FLGC0.938
FNCH0.922
NNOX0.919
ALBO0.916
WKSP0.915
POWL0.912
NBSE0.91
DMRC0.907
10 Most Negative Correlations
PRAA-0.919
DTEA-0.879
AVID-0.875
FCCO-0.873
PINC-0.863
IEP-0.856
PEBK-0.854
PARA-0.853
TUEM-0.851
FOXF-0.849

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Autolus Therapeutics PLC Correlation - Currency/Commodity

The country flag -0.84
( strong negative )
The country flag -0.79
( moderate negative )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag 0.63
( weak )
The country flag -0.63
( weak negative )

Autolus Therapeutics PLC Financials

Annual 2023
Revenue: $1.70M
Gross Profit: $-4.87M (-286.63 %)
EPS: $-1.200
Q4 2023
Revenue: $1.78M
Gross Profit: $0 (0.00 %)
EPS: $-0.440
Q3 2023
Revenue: $406 000
Gross Profit: $24 000.00 (5.91 %)
EPS: $-0.260
Q2 2023
Revenue: $0
Gross Profit: $-1.51M (0.00 %)
EPS: $-0.260

Financial Reports:

No articles found.

Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators